Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Avidan U Neumann

Showing results (61-70 of 83) with videos related to

Pageof 9
Sort By:
AIDS Research and Human Retroviruses|January 11, 2008
Immunodeficiency and intrinsic IFN resistance are associated with viral breakthrough to HCV therapy in HIV-coinfected patientsVeronique Nussenblatt, Mary McLaughlin, Catherine A Rehm, et al.
Plos One|March 11, 2011
Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphismsMartin Lagging, Galia Askarieh, Francesco Negro, et al.
Journal of Hepatology|February 21, 2006
A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patientsVincent G Bain, Kelly D Kaita, Eric M Yoshida, et al.
BMC Gastroenterology|February 2, 2012
Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled studyGeert Bezemer, Arthur R Van Gool, Elke Verheij-Hart, et al.
Allergy|January 21, 2022
Differential effects of lung inflammation on insulin resistance in humans and miceRuth Karlina, Claudia Flexeder, Stephanie Musiol, et al.
The Journal of Infectious Diseases|September 9, 2006
Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infectionAna I Romero, Martin Lagging, Johan Westin, et al.
Allergy|June 5, 2020
Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factorsUrszula Radzikowska, Mei Ding, Ge Tan, et al.
Gastroenterology|March 23, 2010
Ribavirin improves early responses to peginterferon through improved interferon signalingJordan J Feld, Glen A Lutchman, Theo Heller, et al.
Plos One|February 26, 2013
Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infectionJonas Söderholm, Jesper Waldenström, Galia Askarieh, et al.
Hepatology (Baltimore, Md.)|November 30, 2006
IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infectionMartin Lagging, Ana I Romero, Johan Westin, et al.
Pageof 9

Showing results (61-70 of 83) with videos related to

Sort By:
Pageof 9
AIDS Research and Human Retroviruses|January 11, 2008
Immunodeficiency and intrinsic IFN resistance are associated with viral breakthrough to HCV therapy in HIV-coinfected patientsVeronique Nussenblatt, Mary McLaughlin, Catherine A Rehm, et al.
Plos One|March 11, 2011
Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphismsMartin Lagging, Galia Askarieh, Francesco Negro, et al.
Journal of Hepatology|February 21, 2006
A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patientsVincent G Bain, Kelly D Kaita, Eric M Yoshida, et al.
BMC Gastroenterology|February 2, 2012
Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled studyGeert Bezemer, Arthur R Van Gool, Elke Verheij-Hart, et al.
Allergy|January 21, 2022
Differential effects of lung inflammation on insulin resistance in humans and miceRuth Karlina, Claudia Flexeder, Stephanie Musiol, et al.
The Journal of Infectious Diseases|September 9, 2006
Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infectionAna I Romero, Martin Lagging, Johan Westin, et al.
Allergy|June 5, 2020
Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factorsUrszula Radzikowska, Mei Ding, Ge Tan, et al.
Gastroenterology|March 23, 2010
Ribavirin improves early responses to peginterferon through improved interferon signalingJordan J Feld, Glen A Lutchman, Theo Heller, et al.
Plos One|February 26, 2013
Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infectionJonas Söderholm, Jesper Waldenström, Galia Askarieh, et al.
Hepatology (Baltimore, Md.)|November 30, 2006
IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infectionMartin Lagging, Ana I Romero, Johan Westin, et al.
Pageof 9